Inebilizumab: Proposed Mechanism Of Action For Treating Nmosd

Inebilizumab: Proposed Mechanism of Action For Treating NMOSD

Bruce Cree, MD, PhD, MAS: Inebilizumab for NMOSD Treatment

Consistent efficacy of inebilizumab across newly presenting and previously treated NMOSD cases

Inebilizumab in AQP4+ NMOSD patients with history of immunosuppression treatment: N-MOmentum study

Inebilizumab Treatment in Newly Diagnosed NMOSD Patients

Bruce Cree, MD, PhD, MAS: Inebilizumab in Neuromyelitis Optica Spectrum Disorder

Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD

SOLIRIS® (eculizumab) Mechanism of Action for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Recent progress and future needs in NMOSD treatment

Distinctive attributes and efficacy of inebilizumab in NMOSD

Efficacy of inebilizumab in patients with NMOSD with Fc receptor III-A polymorphisms

Kathleen Hawker, MD: Clinical Findings for Satralizumab in Treating NMOSD

403. I-CAN, A Study of Inebilizumab in Children with AQP4+ NMOSD

SRNA

Bruce Cree, MD, PhD, MAS: Insights from the N-MOmentum Study of Inebilizumab

Neuromyelitis optica spectrum disorder | Mechanism of disease

2022 RNDS | What are the long-term treatments for NMOSD and MOGAD?

SRNA

Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder

Research Square

AAN 2021 Highlights: Two-Year Efficacy and Safety Data with Inebilizumab To Treat NMOSD

Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Trial Program

HPR

An overview of the current treatment options for NMOSD from ACTRIMS 2024